“Game-changing Milestone” as Lithoz Beta-TCP Implants Show 92% Success in Long-Term Clinical Evaluation
Austrian ceramic 3D printing company Lithoz has achieved a 92% success rate in a clinical long-term follow-up study of its beta TCP patient-specific implants (PSI). The study confirmed that its 3D printed implants made using Lithoz’s CeraFab printer are effective bone substitutes, showing strong osteoconductive and osteoinductive properties with no post-surgical complications. The study’s findings aim to support the broader clinical adoption of ceramic 3D printing in surgical applications.